Yoneda M, Takatsuki K, Yamauchi K, Oiso Y, Kurokawa M, Kawakubo A, Izuchi K, Tanaka H, Kozawa O, Miura Y
First Department of Internal Medicine, Nagoya University School of Medicine, Japan.
Endocrinol Jpn. 1988 Feb;35(1):121-9. doi: 10.1507/endocrj1954.35.121.
The serum BGP level was assayed in patients with hyperthyroidism (untreated and remittent cases) and hypothyroidism. The mean serum BGP concentration was 9.7 +/- 0.90 ng/ml in 30 patients with untreated hyperthyroidism which was significantly higher than the 2.7 +/- 0.38 ng/ml in 15 remittent patients and 1.3 +/- 0.31 ng/ml in 13 patients with hypothyroidism (p less than 0.001, p less than 0.001). Serum BGP had a significant positive correlation with the concentrations of free triiodothyronine and alkaline phosphatase in the serum, while it had a significant negative correlation with serum PTH. In the patients with hypothyroidism, serum BGP increased significantly in parallel with increases in serum free triiodothyronine with thyroxine therapy. In the patients with hyperthyroidism, serum free triiodothyronine decreased significantly after the first month of methimazole treatment, and fluctuated within the normal range after two months. Serum alkaline phosphatase and BGP did not show significant changes during the first six months of treatment, although they were eventually reduced significantly at the end of one year. These results suggest that thyroid hormone directly stimulates the synthesis and secretion of BGP in existent osteoblasts and also acts on the bone remodeling cycle, therapy accelerating the rate of bone formation; the latter action may occur over a long period.
对甲状腺功能亢进症(未经治疗及缓解期病例)和甲状腺功能减退症患者测定血清骨钙素(BGP)水平。30例未经治疗的甲状腺功能亢进症患者血清BGP平均浓度为9.7±0.90 ng/ml,显著高于15例缓解期患者的2.7±0.38 ng/ml及13例甲状腺功能减退症患者的1.3±0.31 ng/ml(p<0.001,p<0.001)。血清BGP与血清游离三碘甲状腺原氨酸及碱性磷酸酶浓度呈显著正相关,而与血清甲状旁腺激素(PTH)呈显著负相关。在甲状腺功能减退症患者中,甲状腺素治疗后血清BGP随血清游离三碘甲状腺原氨酸升高而显著升高。在甲状腺功能亢进症患者中,甲巯咪唑治疗第一个月后血清游离三碘甲状腺原氨酸显著下降,两个月后在正常范围内波动。治疗前六个月血清碱性磷酸酶和BGP无显著变化,尽管一年末最终显著降低。这些结果表明,甲状腺激素直接刺激现存成骨细胞中BGP的合成与分泌,且作用于骨重塑周期,加速骨形成速率;后一种作用可能在较长时间内发生。